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PERSPECTIVES ON DRUGS 
The EU drugs strategy  
(2013–20) and its action  
plan (2013–16)
EU drugs strategies and action plans direct collective action 
in the field of drugs both within the European Union and at 
international level. They do not impose legal obligations on 
EU Member States but promote a shared model with defined 
priorities, objectives, actions and metrics for measuring 
performance. Member States, and also some candidate 
and pre-accession countries, use this framework to develop 
their own national policy documents, which are increasingly 
synchronised with the EU strategy. They remain free to 
emphasise different national priorities within the overall 
framework of an integrated, balanced and evidence-based 
approach to the drugs problem.
Internationally, the EU drug strategies aim to add value to 
Member States’ policies by offering a platform for coordination 
in relation to international issues and promoting the EU 
approach to tackling the drugs problem. The strategies 
also play an important role in the definition of tasks for 
EU institutions, bodies and agencies, and are taken into 
consideration by the European Commission when setting 
funding priorities in the drugs field.
A final external evaluation of the previous EU drug strategy 
(2005–12) found that it provided a forum for consensus 
building and decision-making and a platform for information 
sharing and mutual learning. It also enhanced the ‘voice’ 
of the EU in international fora and promoted a culture of 
harmonised data collection and best practices identification. 
The review recommended, among others, to further promote 
the development and use of evidence for drug policy, as 
there remain instances of insufficient evidence about the 
effectiveness of specific measures. 
The EU drugs strategy (2013–20) and the 
EU action plan (2013–16) were endorsed 
by the Justice and Home Affairs Council 
of the European Union respectively on 
7 December 2012 and on 6 June 2013. 
The main features of the current strategy 
and its first action plan, and how they 
aim to address Europe’s changing drugs 
problem, are presented in this analysis.
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I  A new strategy…
The EU drugs strategy (2013–20) constitutes the ninth 
strategic document on illicit drugs endorsed by EU Member 
States since 1990 and presents their current drug policy 
position and aspirations, identifying common objectives to 
reduce drug demand, dependence, related health and social 
harms, and supply. The implementation of its long-term 
objectives draws on more operational documents allowing 
progressive achievement and mid-term review. Then two 
consecutive four-year action plans translate the strategic 
priorities into specific actions with a timetable, responsible 
parties, indicators and assessment sources. These are drafted 
by the corresponding EU Presidencies in 2013 and 2017. 
The first of these was adopted under the Irish Presidency of 
the EU in June 2013. It is structured around two policy areas: 
drug demand reduction and drug supply reduction; and three 
cross-cutting themes: coordination; international cooperation; 
and information, research, monitoring and evaluation. It 
includes 16 objectives and 54 actions and it spans across 
these five pillars. The plan sets a number of Reitox/EMCDDA 
over-arching indicators to facilitate the measurement of the 
overall effectiveness of implementation. A second action plan 
for the period 2017–20 will be prepared following an external 
mid-term assessment of the EU drugs strategy by 2016. 
I  …responding to new challenges in the drugs market
There are a number of significant changes in the EU drugs 
market which the 2013–20 strategy aims to address. In 
particular the rapid increase in number of new psychoactive 
substances becoming available on the market as well as 
diversification in drug trafficking routes and methods of 
transport are among the challenges that Member States now 
face. In particular, the new plan aims at enhancing effective 
law enforcement coordination and cooperation as well as 
effective judicial cooperation and legislation within the EU in 
order to respond effectively to current and emerging trends 
in illicit drug activity. The strategy also proposes that special 
attention be paid to communication technologies, which 
play a significant role in the spread of drugs, particularly new 
psychoactive substances. It calls for the development of 
alternatives to traditional law enforcement approaches, which 
it recognises are increasingly challenged by issues such as 
the combined use of illicit drugs and alcohol, the misuse of 
prescription medicines, as well as the so-called ‘legal highs’ 
phenomenon.
I  …addressing health and social issues
For the first time, the 2013–20 strategy incorporates the 
‘reduction of the health and social risks and harms caused by 
drugs’ as a policy objective, alongside the two traditional drug 
policy aims of reducing supply and demand. The action plan 
2013–16 addresses in particular the need to ensure the quality 
of policy interventions, requiring for instance Member States 
to agree and commence the implementation of EU minimum 
quality standards in demand reduction. The role of civil society 
in the drug policy-making process is also enhanced, with 
regular dialogues envisaged between the Civil Society Forum 
and the Horizontal Working Party on Drugs (HDG) of the 
I  Facts and figures 
European Union: 
Member States: 28 in 2014 
Population: 503.6 million
Surface: 4 million km2
EU drugs strategies: 
First European plan to combat drugs: 1990
Horizontal working party on drugs: 1997
First EU drugs strategy: 2000
First evaluation of a EU drugs strategy: 2004
First external evaluation of a EU drugs strategy: 2012
Interactive: world regional strategies available on the EMCDDA website: emcdda.
europa.eu/topics/pods/eu-drugs-strategy-2013-20
I  Interactive element: map
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Council of the European Union. The social reintegration and 
recovery of all drug users are expected to receive increased 
attention over the eight-year period as the ultimate goal of 
drug treatment services. Drug use in prison has also been 
given increased emphasis, to ensure that the care received by 
drug users in penal institutions is equivalent to that provided 
by health services in the community.
I  … and supporting evidence-based decision making
The new strategy stresses the need for an empirical and 
evidence-based approach to drugs policy. It expands the main 
principles on which international drugs policies are based 
by adding the principle of evidence-based decision-making 
to the integrated and balanced approach enshrined in the 
2009 UN political declaration on drugs. The strategy outlines 
a model for EU drugs policy that is: integrated, combining all 
aspects of drugs activities; balanced, concentrating equally 
on demand and supply reduction measures; and evidence-
based, drawing on scientific findings. It aims for an improved 
understanding of the impact of drug policy measures, the 
adoption of quality standards and best practices in drug 
demand reduction alongside the implementation of key 
indicators to measure success in the area of drug supply 
reduction. The strategy provides Member States with a forum 
for open debate about the effectiveness of demand reduction 
measures and, increasingly, supply reduction measures, and 
explicitly supports drug monitoring and collection of data on 
best practices.
Alongside the European Union bodies, other international 
organisations have developed regional drug strategies and 
action plans in recent years. These now cover 147 countries 
in four continents (see online interactive map). 
 
In the Americas, the Organization of American States (OAS) 
adopted the Hemispheric Drug Strategy in 2010 and, a 
year later, a Plan of Action (2011–15) to implement the 
strategy’s objectives. In parallel, the Andean Community 
adopted its own drug strategy 2012–19 and action plan 
2012–16. 
 
 In Africa, the African Union (AU) adopted the Plan of Action 
on drug control (2013–17), while the Economic Community 
of West African States (ECOWAS) adopted the Regional 
Action Plan to Address the Growing Problem of Illicit Drug 
Trafficking, Organised Crime and Drug Abuse 2008–11. 
 
In Asia, the Association of Southeast Asian Nations 
(ASEAN) adopted the Work Plan on Combating Illicit Drug 
Production, Trafficking, and Use 2009–15, with the aim 
of achieving a drug-free region. In addition, the Shanghai 
Cooperation Organisation (SCO) aims to drastically reduce 
the scale of trafficking in and consumption of drugs and 
precursors through the Counternarcotic Strategy of the 
SCO Member States 2011–16. 
 
The objectives and content of these strategies reflect 
differences in drug situations and available resources 
between the regions where they are to be implemented. 
There is however also a certain degree of similarity in key 
policy areas, such as supply reduction, or and a common 
use of a comprehensive approach to reduce both drugs 
supply and demand. The increasing number of regional 
strategies also reflects a growing understanding that drugs 
are an issue that cannot be tackled only at the national 
level and that coordinated regional approaches to common 
problems can be developed. 
 
 
Timeline: other regional drugs strategies  
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